Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms

Phase 3

Completed

Conditions: Posttraumatic Stress Disorder

First Posted Date: 2007-02-27

Last Posted Date: 2007-02-27

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 40

Registration Number: NCT00440713

Aripiprazole for the Treatment of Refractory Anxiety

Phase 4

Completed

Conditions: Generalized Anxiety Disorder
Panic Disorder

First Posted Date: 2007-02-22

Last Posted Date: 2009-08-10

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00438386

Locations: 🇺🇸
Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Aripiprazole
Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine

First Posted Date: 2007-01-18

Last Posted Date: 2016-11-02

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 215

Registration Number: NCT00423878

Locations: 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸
John C Corrigan Community Mental Health Center, Fall River, Massachusetts, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 25 locations

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: Aripiprazole

First Posted Date: 2007-01-11

Last Posted Date: 2017-04-18

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 12

Registration Number: NCT00420459

Locations: 🇺🇸
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, United States

Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

Phase 4

Conditions: Schizophrenia

First Posted Date: 2006-11-06

Last Posted Date: 2009-02-18

Lead Sponsor: Universita di Verona

Target Recruit Count: 106

Registration Number: NCT00395915

Locations: 🇮🇹
University of Verona, Verona, Italy

Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2006-10-25

Last Posted Date: 2014-02-12

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 111

Registration Number: NCT00392197

Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)

Not Applicable

Completed

Conditions: Schizophrenia OCD
Obsessive Compulsive Disorder

First Posted Date: 2006-09-11

Last Posted Date: 2011-09-16

Lead Sponsor: Jamaica Hospital Medical Center

Target Recruit Count: 10

Registration Number: NCT00374348

Locations: 🇺🇸
Jamaica Hospital Medical Center Department of Psychiatry, Jamaica, New York, United States

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Phase 3

Completed

Conditions: Autistic Disorder
Behavioral Symptoms

Interventions: Drug: Aripiprazole

First Posted Date: 2006-08-18

Last Posted Date: 2013-12-02

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 330

Registration Number: NCT00365859

Locations: 🇺🇸
Institute For Behavioral Medicine, Smyrna, Georgia, United States
🇺🇸
Regions Hospital, St. Paul, Minnesota, United States
🇺🇸
Harmonex Neuroscience, Dothan, Alabama, United States

and more 52 locations